MedPath

Utility of 2- Octyl Cyanoacrylate (2-OCA)

Not Applicable
Conditions
Ascites
Fluid Loss
Interventions
Other: Dermabond
Registration Number
NCT05278013
Lead Sponsor
Methodist Health System
Brief Summary

Paracentesis is a commonly performed procedure in the inpatient and outpatient settings for treatment of ascites. The most frequent complication of paracentesis is fluid leak. Risk for this complication can be reduced by following the Z-track technique; however, fluid leaks still occur causing significant morbidity. 2-Octyl cyanoacrylate (2-OCA, Dermabond manufactured by Ethicon Inc) skin adhesive has been used for years for skin closure for wounds from surgical incisions including punctures from minimally invasive surgery and simple trauma lacerations.

Detailed Description

Paracentesis is a commonly performed procedure in the inpatient and outpatient settings for treatment of ascites. The most frequent complication of paracentesis is fluid leak. Risk for this complication can be reduced by following the Z-track technique; however, fluid leaks still occur causing significant morbidity. 2-Octyl cyanoacrylate (2-OCA, Dermabond manufactured by Ethicon Inc) skin adhesive has been used for years for skin closure for wounds from surgical incisions including punctures from minimally invasive surgery and simple trauma lacerations. It has also been used for treatment of ascites fluid leaks following paracentesis with success in case reports. While the initial FDA approval included a contraindication for use on mucosal surfaces, some evidence in literature suggests that use on mucosal surfaces might warrant further investigation. For example, 2-OCA has been used for repair of a lacerated tongue of a pediatric patient and for closure of congenital cleft lips

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
All
Target Recruitment
134
Inclusion Criteria
  • Inpatients at Methodist Dallas Medical Center (MDMC) ≥18 years of age with ascites requiring therapeutic paracentesis performed by the procedure team at the bedside.
Exclusion Criteria
  • Paracentesis procedures performed in the interventional radiology department or by physicians outside of the procedure team.
  • Patients who undergo a liver transplant surgery or other abdominal surgeries within 48 hours from the paracentesis procedure.
  • Patients that undergo paracentesis using a device or kit other than the 18 gauge Safe-T-Centesis kit

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Glue Group (GG)DermabondRandomization will take place utilizing serial randomization to Glue Group (GG) and No Glue Group (NG) where skin closure will be assigned serially to a week of GG alternating with a week NG.
Primary Outcome Measures
NameTimeMethod
Incidence of bleeding from siteup to 1 year.

local irritation/burning, infections, and/or perforation within 48 hours post-procedure and topical 2-OCA application.

Number of participants with Evidence of Skin Reactionsup to 1 year

itching, burning, sensation, redness, dermatitis

Access the rate of complicationsup to 1 year

Assess the rate of complications after topical 2-OCA application post-paracentesis such as skin infections, peritonitis, perforation of viscus, and bleeding.

Access post-paracentesis fluid leaksup to 1 year

Incidence of post-paracentesis fluid leaks within 48 hours of paracentesis and topical 2-OCA application

Access topical 2-OCA applicationup to 1 year

To assess if topical 2-OCA application for skin closure would prevent post-paracentesis fluid leaks.

Number of participants with complications from paracentesis procedureup to 1 year

Cellulitis, peritonitis, bleeding, perforated viscus

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Methodist Dallas Medical Center Pharmacy

🇺🇸

Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath